Clinical Trial Update: A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating gemcitabine/nab-paclitaxel (GnP) plus serplulimab and stereotactic body radiation therapy as first-line treatment for locally …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• Serplulimab (serplulimab)

Snippet

Sponsor: West China Hospital | Conditions: Locally Advanced Pancreatic Ductal Adenocarcinoma | Phase 2 | Status: RECRUITING